trending Market Intelligence /marketintelligence/en/news-insights/trending/ukylep1a2y7kkz_cn5xfyq2 content esgSubNav
In This List

Knight Therapeutics secures Canadian rights to Ardelyx drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Knight Therapeutics secures Canadian rights to Ardelyx drug

Ardelyx Inc. sold the Canadian rights to its medicine tenapanor to Knight Therapeutics Inc.

The medicine has been evaluated in a late-stage trial to treat irritable bowel syndrome with constipation and is being studied in a second phase 3 study for hyperphosphatemia, which causes an abnormally elevated level of phosphate in the blood.

Fremont, Calif.-based Ardelyx will receive C$25 million for the rights. The amount includes an undisclosed up-front payment from Montreal-based Knight Therapeutics.

In December 2017, Ardelyx sold the rights to develop and commercialize the drug in China to Shanghai Fosun Pharmaceutical (Group) Co. Ltd. for an up-front payment of $12 million.